Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03363126
Other study ID # CE_20160404_1_WEI
Secondary ID
Status Completed
Phase N/A
First received November 30, 2017
Last updated November 30, 2017
Start date September 1, 2015
Est. completion date June 20, 2016

Study information

Verified date November 2017
Source Fondation Ophtalmologique Adolphe de Rothschild
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Endoscopic endonasal transsphenoidal surgery is a procedure for the treatment of pituitary macroadenomas that cause visual impairment through optic chiasm compression. The aim of this retrospective study is to describe visual outcome after this procedure.


Recruitment information / eligibility

Status Completed
Enrollment 88
Est. completion date June 20, 2016
Est. primary completion date February 10, 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Pituitary tumor causing optic chiasm compression (documented on MRI or CT-scan)

- Visual impairment caused by chiasm compression

- Treatment by transsphenoidal endonasal surgery

- Treatment in the Rothschild Foundation (Paris) between 2009 and 2013

Exclusion Criteria:

- Ophtalmologic condition other than optic chiasm compression

Study Design


Intervention

Procedure:
Endonasal transsphenoidal pituitary tumor removal
Removal of pituitary tumor by transsphenoidal endonasal surgery

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Fondation Ophtalmologique Adolphe de Rothschild

Outcome

Type Measure Description Time frame Safety issue
Primary Post-operative gain in visual acuity Difference between pre-operative and post-operative visual acuity, expressed in LogMAR six months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04529356 - The TMS Treatment for Postoperative Headache in GH Tumor N/A
Completed NCT04212793 - Detection of PitNET Tissue During TSS Using Bevacizumab-800CW Phase 1
Recruiting NCT03309319 - A Pilot Study of Rosiglitazone in the Treatment of GH Secreting Pituitary Adenomas N/A
Terminated NCT04106531 - Validation of a Quality of Life Metric "Prolac-10"
Recruiting NCT03719781 - Postoperative Cognitive Dysfunction in Patients Undergoing Pituitary Removal Surgery
Recruiting NCT01556230 - Prospective Study of Clinically Nonfunctioning Pituitary Adenomas
Recruiting NCT03132259 - Comparative Low and High Dose of Dexmedethomidine in Pituitary Tumor Removal by Transphenoid Approach Phase 4
Recruiting NCT01368133 - The Observational Study of Growth Hormone-secreting Pituitary Tumors N/A
Withdrawn NCT04863339 - Tranexamic Acid for Blood Loss Minimization in Endoscopic Pituitary Surgery Phase 2
Terminated NCT00646308 - Assessment of Cardiovascular Risk Markers in Growth Hormone Deficient Patients With Nonsecreting Pituitary Adenomas N/A
Recruiting NCT00852501 - Characterization of Receptors in Non-functioning Pituitary Macroadenomas Phase 4
Completed NCT03465423 - Comparison of Propofol Requirement Between Patients With Pituitary Somatotroph Tumor and With Nonfunctioning Pituitary Tumor in Transsphenoidal Pituitary Surgery Under Total Intravenous Anesthesia
Recruiting NCT03474601 - Seoul National University Pituitary Disease Cohort Study
Recruiting NCT05139277 - Evaluation of the CONVIVO System N/A
Active, not recruiting NCT03636568 - Hyponatremia Study (Delayed Hyponatremia After Pituitary Surgery) N/A
Completed NCT02813044 - Effects of Total Intravenous Anesthesia With Propofol-remifentanil Versus Inhalational Anesthesia With Sevoflurane on Quality of Recovery in Patients Undergoing Transsphenoidal Surgery for Pituitary Tumor N/A
Recruiting NCT03973450 - Epidemiology of Pituitary Tumours: Prevalence of Associated Neoplasia
Active, not recruiting NCT04042753 - Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors Phase 2
Recruiting NCT04018963 - The Impact of Endoscopic Pituitary Surgery on Nasal Function
Not yet recruiting NCT04938401 - Construction and Application of a Risk Prediction Model Forepistaxis After Pituitary Tumor Resection